The mobile applications and digital infrastructure of Brighter's award-winning service for insulin treated diabetics - Actiste® Diabetes Management as a Service - are now CE certified. The applications are offered exclusively to Actiste subscribers.
Within the requirements of the certification process, user tests have been completed on both iOS and Android. The tests were conducted with impartial participants up to the age of 70 and have received a very positive response. The main focus areas for the application tests were user-friendliness and the ability to get support. Within these areas the solution has achieved positive reviews equivalent to 92% of the maximum possible.
"We are incredibly pleased with the test results of the app and The Benefit Loop®, the core and heart of our unique diabetes service," says Truls Sjöstedt, Brighter's CEO and founder. "Through The Benefit Loop, we connect all relevant parties in the care chain; the patient receives support and guidance, relatives can monitor and the caregivers can adapt and improve. As a large group of Actiste users are expected to be relatively unaccustomed to apps, we are particularly proud to have achieved basically the best possible rating in the support functionality tests."
"The model is based on a Multi-Sided Market Platform strategy, in which Brighter, by increasing access to valid health data, creates value for all stakeholders in the care chain: patients and their relatives and close associates, healthcare providers, R&D and research institutes, the pharmaceutical industry, and society as a whole," says Truls Sjöstedt.
Actiste consists of a unique and patented device reducing the number of steps needed to manage diabetes by 67 percent, and a digital infrastructure for smart services, healthcare contact, subscriptions for consumables, data management and personal coaching stimulating behavioral change and increased adherence in treatments. The service is initially introduced to markets in the GCC, Southeast Asia and the Nordics.
The potential in the company's 14 initial target markets is estimated (http://news.cision.com/brighter-ab--publ-/r/brighter-defines-market-vision-for-actiste-until-2023-on-5-continents-,c2571329) over 30 million sold Actiste subscriptions.
Based on the prevailing market conditions and expected future market situation, Brighter has identified (http://news.cision.com/brighter-ab--publ-/r/brighter-announces-actiste-pricing-,c2593488) an average consumer price for Actiste of approximately EUR 60 per month, for the basic level subscription, including data sharing only with relatives and their close associates. For more extensive subscriptions, the price could range up to EUR 110 per month. The price is also affected to a certain extent by regional healthcare systems and societal conditions.
For further information, please contact:
Truls Sjöstedt, CEO
Telefon: +46 709 73 46 00
Henrik Norström, COO
Telefon: +46 733 40 30 45
Brighter's solution Actiste® handles most of the self-monitoring and treatment of insulin-treated diabetes in a single easy-to-use device. Measurement of glucose levels, insulin injections, automatic logging, and timing of all activities are performed from a single unit. Actiste is connected via an autonomous and secure mobile connection, and information can be automatically shared with selected recipients through The Benefit Loop®, Brighter's open cloud-based service where data is collected, processed and analyzed with patient consent.
Validated user-generated data, such as glucose levels or insulin doses, can be automatically transferred electronically to many different constituents. The patient selects when and how data is shared and who will have access to it. Through The Benefit Loop, different services can motivate patients with chronic illnesses to change their behavior, which can save lives, reduce relatives' concerns, and release enormous healthcare resources. www.actiste.com
Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of healthcare's biggest challenges: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing, and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop® - is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and their close associates, healthcare providers, research institutes, the pharmaceutical industry, and society as a whole. www.brighter.se
The Company's shares are listed on NASDAQOMX First North/BRIG (http://www.nasdaqomxnordic.com/shares/microsite?Instrument=SSE86375). Brighter's Certified Adviser on Nasdaq OMX First North is Eminova Fondkommission AB, +46 (0)8 - 684 211 00, email@example.com, www.eminova.se.
This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 15:40 CET on September 19, 2018.
This information was distributed by Cision http://www.cisionwire.se/